

1. INTRODUCTIONS

There were no new members on the call. !

Participants to the call:

Alric Rüther
Elie Akl
Ivan Florez
Jerry Osheroff
Michael McCaul
Mireille Goetghebeur
Newman Dieyi
Nichole Taske
Per Olav Vandvik
Tamara Kredo
Xuan Yu

Secretariat: Anna Dion, David Tovey, Safa Al-Khateeb

2. FOLLOW-UP ON ACTION ITEMS

a. Papers on rapid guideline assessment

- i. Article 1:** <https://health-policy-systems.biomedcentral.com/articles/10.1186/s12961-018-0327-8>
- ii. Article 2:** <https://health-policy-systems.biomedcentral.com/articles/10.1186/s12961-018-0329-6>
- iii. Article 3:** <https://health-policy-systems.biomedcentral.com/articles/10.1186/s12961-018-0330-0>

Ivan asked people to read through articles above about rapid guideline assessment!
At next week's meeting, group to discuss relevance for COVID-related guidelines and what would be defined as "good enough" trustworthy guidelines in context of COVID.!
GRADE working on finalizing article describing urgent guidelines. Once gone through GRADE approval process, Eli to share with group !
Opportunity to also translate learnings for relevance to HTA assessment!

3. TERMS OF REFERENCE AND OBJECTIVES

- a. Review items 7, 8, and 9 in terms of reference (see attachment 3)**

Item #7 describes under-taking quality assessments of guidelines. May be opportunities to link to other groups are currently doing in this space. Will be discussed in more detail in agenda item 4

4. GUIDANCE ACTIVITIES

- a. List and appraise COVID-related clinical practice guidelines, complementing and building on existing initiatives (ECRI, NIPH, others) (see attachment 4)**

Newman walked the group through the background document he had prepared comparing different approaches to guideline assessment between ECRI, NIPH/FHI and a group led by Yannaetz in the Middle East

Explained that these are most promising resources we found, though not perfect; part of Newman's work is to assess the extent that quality is considered within that context

Per suggested including assessment of navigation / usefulness as additional criteria

Different quality assessments prioritize different quality criteria (e.g. stakeholder involvement, rigour in guideline development, etc). Given variations in need and context, likely need flexibility across this space, while supporting transparency of criteria and how they are weighted, allowing end-users to select guidance, knowing how it has been developed and how to adapt to their context

Group discussed whether repository should include complete range of guidelines (rather than just high-quality ones) to be align with end-user needs. Group agreed to re-visit this question at a later meeting

- b. COVID-19 guideline appraisal shared by Tamara (see attachment 5)**

- i. Checking PROSPERO for other groups doing or planning this – could be part of potential collaboration efforts**

This was not discussed- to be carried forward to next meeting !

5. WORKING GROUP ACHIEVEMENTS STATEMENT

- a. Recommending evidence-based approaches in ways that are more coordinated and efficient and that balance quality and timeliness: possibly guideline registration, inventory and quality rating**

6. ANY OTHER BUSINESS